Filipa Marques Ferreira
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Filipa Marques Ferreira has a total of 124 co-authors. Here are the top co-authors by number of shared publications:
- Thorsten Buch
Institute of Laboratory Animal Science, University of Zurich, Schlieren, Switzerland
7 shared publications - Andreas Lutterotti
Cellerys AG, Wagistrasse 21, Schlieren, Switzerland
2 shared publications Jon D. Laman
Department of Biomedical Sciences of Cells and Systems, University Medical Center Groningen (UMCG), University of Groningen, Groningen, The Netherlands
2 shared publications- Pietro Oldrati
Cellerys AG, Wagistrasse 21, Schlieren, Switzerland
2 shared publications Pushpalatha Palle
Benaroya Research Institute at Virginia Mason, Seattle, WA, USA
2 shared publications- Roland Martin
Institute of Experimental Immunology, University of Zurich, 8057 Zurich, Switzerland; Cellerys AG, Wagistrasse 21, 8952 Schlieren, Switzerland; Neuroimmunology and MS Research, Neurology Clinic, University Hospital Zurich, University of Zurich, 8091 Zurich, Switzerland; Therapeutic Immune Design Unit, Department of Clinical Neuroscience, Karolinska Institute, Center for Molecular Medicine, 17177 Stockholm, Sweden
2 shared publications
Latest Publications
- Open Access
- 9 October 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (41)
Kupffer cells are key mediators of antigen-specific immune tolerance by peptide-coupled red blood cells
Induction of antigen-specific immune tolerance is the most precise method for reverting an autoreactive immune response in diseases such as multiple sclerosis (MS). Coupling red blood cells (RBCs) with a cocktail of MS immunodominant peptides is a promising approach to induce antigen-specific immune tolerance in patients. Here, we show that RBCs coupled with disease-inducing antigen efficiently prevent the development of experimental autoimmune encephalomyelitis, when administered prophylactically, and ameliorate disease symptoms when given therapeutically. The tolerogenic activity of peptide-coupled RBCs (pcRBC) was antigen specific and dependent on both cell and peptide dose. Kupffer cells (KC) were the primary phagocytes of pcRBC, and their uptake of pcRBC did not require complement component 3, SIRPα, and Stabilin 1 and 2. KC were indispensable for the induction of tolerance, which was accompanied by programmed death-ligand 1 up-regulation and a tolerogenic transcriptional shift. Our findings establish KC as central mediators of pcRBC-induced immune tolerance and provide mechanistic insight for the use of this therapeutic strategy in autoimmune disease.
- 9 October 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (41)
Open AccessKupffer cells are key mediators of antigen-specific immune tolerance by peptide-coupled red blood cells
Induction of antigen-specific immune tolerance is the most precise method for reverting an autoreactive immune response in diseases such as multiple sclerosis (MS). Coupling red blood cells (RBCs) with a cocktail of MS immunodominant peptides is a promising approach to induce antigen-specific immune tolerance in patients. Here, we show that RBCs coupled with disease-inducing antigen efficiently prevent the development of experimental autoimmune encephalomyelitis, when administered prophylactically, and ameliorate disease symptoms when given therapeutically. The tolerogenic activity of peptide-coupled RBCs (pcRBC) was antigen specific and dependent on both cell and peptide dose. Kupffer cells (KC) were the primary phagocytes of pcRBC, and their uptake of pcRBC did not require complement component 3, SIRPα, and Stabilin 1 and 2. KC were indispensable for the induction of tolerance, which was accompanied by programmed death-ligand 1 up-regulation and a tolerogenic transcriptional shift. Our findings establish KC as central mediators of pcRBC-induced immune tolerance and provide mechanistic insight for the use of this therapeutic strategy in autoimmune disease.
- Open Access
- 31 August 2026
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 123 (36)
Treatment of multiple sclerosis with peptide-coupled red blood cells induces antigen-specific T regulatory cells
Inducing antigen-specific immune tolerance is a long-standing aim in organ-specific autoimmune diseases including multiple sclerosis (MS). We developed a therapy based on autologous red blood cells (RBCs) as tolerizing carriers of autoantigens and tested these in an open-label, dose-escalation, phase Ib clinical trial with clinical, imaging, and mechanistic readouts. RBCs coupled with seven immunodominant myelin peptides (pcRBCs) were safe and well tolerated. Several clinical and imaging readouts remained stable, which was supported by a reduction of neurofilament light chain indicating reduced tissue inflammation in the brain. Single-cell RNA sequencing identified expansion of antigen-specific CD4+ memory T cells with regulatory phenotypes and loss of proinflammatory cells three months after a single administration of pcRBCs. This was corroborated by a reduction of autoreactive CD4+ T cell responses and an early increase of IL-10, Tr1 regulatory T cells and tolerogenic monocytes and plasmacytoid dendritic cells. Biodistribution studies in mice and humans demonstrate that pcRBCs are rapidly processed by Kupffer cells in the liver and by marginal zone macrophages in the spleen. In summary, pcRBCs are a promising autologous cell therapy for achieving antigen-specific immune tolerance in MS.
- 31 August 2026
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 123 (36)
Open AccessTreatment of multiple sclerosis with peptide-coupled red blood cells induces antigen-specific T regulatory cells
Inducing antigen-specific immune tolerance is a long-standing aim in organ-specific autoimmune diseases including multiple sclerosis (MS). We developed a therapy based on autologous red blood cells (RBCs) as tolerizing carriers of autoantigens and tested these in an open-label, dose-escalation, phase Ib clinical trial with clinical, imaging, and mechanistic readouts. RBCs coupled with seven immunodominant myelin peptides (pcRBCs) were safe and well tolerated. Several clinical and imaging readouts remained stable, which was supported by a reduction of neurofilament light chain indicating reduced tissue inflammation in the brain. Single-cell RNA sequencing identified expansion of antigen-specific CD4+ memory T cells with regulatory phenotypes and loss of proinflammatory cells three months after a single administration of pcRBCs. This was corroborated by a reduction of autoreactive CD4+ T cell responses and an early increase of IL-10, Tr1 regulatory T cells and tolerogenic monocytes and plasmacytoid dendritic cells. Biodistribution studies in mice and humans demonstrate that pcRBCs are rapidly processed by Kupffer cells in the liver and by marginal zone macrophages in the spleen. In summary, pcRBCs are a promising autologous cell therapy for achieving antigen-specific immune tolerance in MS.
- Open Access
- 8 March 2023
- Published by Springer Nature in Acta Neuropathologica Communications
- Vol. 11 (1) , 1-19
Insulin-like growth factor-1 receptor controls the function of CNS-resident macrophages and their contribution to neuroinflammation
Signaling by insulin-like growth factor-1 (IGF-1) is essential for the development of the central nervous system (CNS) and regulates neuronal survival and myelination in the adult CNS. In neuroinflammatory conditions including multiple sclerosis (MS) and its animal model experimental autoimmune encephalomyelitis (EAE), IGF-1 can regulate cellular survival and activation in a context-dependent and cell-specific manner. Notwithstanding its importance, the functional outcome of IGF-1 signaling in microglia/macrophages, which maintain CNS homeostasis and regulate neuroinflammation, remains undefined. As a result, contradictory reports on the disease-ameliorating efficacy of IGF-1 are difficult to interpret, together precluding its potential use as a therapeutic agent. To fill this gap, we here investigated the role of IGF-1 signaling in CNS-resident microglia and border associated macrophages (BAMs) by conditional genetic deletion of the receptorIgf1rin these cell types. Using a series of techniques including histology, bulk RNA sequencing, flow cytometry and intravital imaging, we show that absence of IGF-1R significantly impacted the morphology of both BAMs and microglia. RNA analysis revealed minor changes in microglia. In BAMs however, we detected an upregulation of functional pathways associated with cellular activation and a decreased expression of adhesion molecules. Notably, genetic deletion ofIgf1rfrom CNS-resident macrophages led to a significant weight gain in mice, suggesting that absence of IGF-1R from CNS-resident myeloid cells indirectly impacts the somatotropic axis. Lastly, we observed a more severe EAE disease course uponIgf1rgenetic ablation, thus highlighting an important immunomodulatory role of this signaling pathway in BAMs/microglia. Taken together, our work shows that IGF-1R signaling in CNS-resident macrophages regulates the morphology and transcriptome of these cells while significantly decreasing the severity of autoimmune CNS inflammation.
- 8 March 2023
- Published by Springer Nature in Acta Neuropathologica Communications
- Vol. 11 (1) , 1-19
Open AccessInsulin-like growth factor-1 receptor controls the function of CNS-resident macrophages and their contribution to neuroinflammation
Signaling by insulin-like growth factor-1 (IGF-1) is essential for the development of the central nervous system (CNS) and regulates neuronal survival and myelination in the adult CNS. In neuroinflammatory conditions including multiple sclerosis (MS) and its animal model experimental autoimmune encephalomyelitis (EAE), IGF-1 can regulate cellular survival and activation in a context-dependent and cell-specific manner. Notwithstanding its importance, the functional outcome of IGF-1 signaling in microglia/macrophages, which maintain CNS homeostasis and regulate neuroinflammation, remains undefined. As a result, contradictory reports on the disease-ameliorating efficacy of IGF-1 are difficult to interpret, together precluding its potential use as a therapeutic agent. To fill this gap, we here investigated the role of IGF-1 signaling in CNS-resident microglia and border associated macrophages (BAMs) by conditional genetic deletion of the receptorIgf1rin these cell types. Using a series of techniques including histology, bulk RNA sequencing, flow cytometry and intravital imaging, we show that absence of IGF-1R significantly impacted the morphology of both BAMs and microglia. RNA analysis revealed minor changes in microglia. In BAMs however, we detected an upregulation of functional pathways associated with cellular activation and a decreased expression of adhesion molecules. Notably, genetic deletion ofIgf1rfrom CNS-resident macrophages led to a significant weight gain in mice, suggesting that absence of IGF-1R from CNS-resident myeloid cells indirectly impacts the somatotropic axis. Lastly, we observed a more severe EAE disease course uponIgf1rgenetic ablation, thus highlighting an important immunomodulatory role of this signaling pathway in BAMs/microglia. Taken together, our work shows that IGF-1R signaling in CNS-resident macrophages regulates the morphology and transcriptome of these cells while significantly decreasing the severity of autoimmune CNS inflammation.
- 26 April 2019
- Published by Springer Nature in Journal of Molecular Medicine
- Vol. 97 (7) , 889-896
Bone marrow chimeras—a vital tool in basic and translational research
Bone marrow chimeras are used routinely in immunology research as well as in other fields of biology. Here, we provide a concise state-of-the-art review about the types of chimerisms that can be achieved and the type of information that each model generates. We include separate sections for caveats and future developments. We provide examples from the literature in which different types of chimerism were employed to answer specific questions. While simple bone marrow chimeras allow to dissect the role of genes in distinct cell populations such as the hematopoietic cells versus non-hematopoietic cells, mixed bone marrow chimeras can provide detailed information about hematopoietic cell types and the intrinsic and extrinsic roles of individual genes. The advantages and caveats of bone marrow chimerism for the study of microglia are addressed, as well as alternatives to irradiation that minimize blood-brain-barrier disruption. Elementary principles are introduced and their potential is exemplified through summarizing recent studies.
- 26 April 2019
- Published by Springer Nature in Journal of Molecular Medicine
- Vol. 97 (7) , 889-896
Bone marrow chimeras—a vital tool in basic and translational research
Bone marrow chimeras are used routinely in immunology research as well as in other fields of biology. Here, we provide a concise state-of-the-art review about the types of chimerisms that can be achieved and the type of information that each model generates. We include separate sections for caveats and future developments. We provide examples from the literature in which different types of chimerism were employed to answer specific questions. While simple bone marrow chimeras allow to dissect the role of genes in distinct cell populations such as the hematopoietic cells versus non-hematopoietic cells, mixed bone marrow chimeras can provide detailed information about hematopoietic cell types and the intrinsic and extrinsic roles of individual genes. The advantages and caveats of bone marrow chimerism for the study of microglia are addressed, as well as alternatives to irradiation that minimize blood-brain-barrier disruption. Elementary principles are introduced and their potential is exemplified through summarizing recent studies.
- 13 April 2019
- Published by Springer Nature in Journal of Molecular Medicine
- Vol. 97 (6) , 871-877
Benefits of a factorial design focusing on inclusion of female and male animals in one experiment
Disease occurrence, clinical manifestations, and outcomes differ between men and women. Yet, women and men are most of the time treated similarly, which is often based on experimental data over-representing one sex. Accounting for persisting sex bias in biomedical research is the misconception that the analysis of sex-specific effects would double sample size and costs. We designed an analysis to test the potential benefits of a factorial study design in the context of a study including male and female animals. We chose a 2 × 2 factorial design approach to study the effect of treatment, sex, and an interaction term of treatment and sex in a hypothetical situation. We calculated the sample sizes required to detect an effect of a given magnitude with sufficient power and under different experimental setups. We demonstrated that the inclusion of both sexes in experimental setups, without testing for sex effects, requires no or few additional animals in our scenarios. These experimental designs still allow for the exploration of sex effects at low cost. In a confirmatory instead of an exploratory design, we observed an increase in total sample sizes by 33%, at most. Since the complexities associated with this mathematical model require statistical expertise, we generated and provide a sample size calculator for planning factorial design experiments. For the inclusion of sex, a factorial design is advisable, and a sex-specific analysis can be performed without excessive additional effort. Our easy-to-use calculation tool provides help in designing studies with both sexes and addresses the current sex bias in preclinical studies.
- 13 April 2019
- Published by Springer Nature in Journal of Molecular Medicine
- Vol. 97 (6) , 871-877
Benefits of a factorial design focusing on inclusion of female and male animals in one experiment
Disease occurrence, clinical manifestations, and outcomes differ between men and women. Yet, women and men are most of the time treated similarly, which is often based on experimental data over-representing one sex. Accounting for persisting sex bias in biomedical research is the misconception that the analysis of sex-specific effects would double sample size and costs. We designed an analysis to test the potential benefits of a factorial study design in the context of a study including male and female animals. We chose a 2 × 2 factorial design approach to study the effect of treatment, sex, and an interaction term of treatment and sex in a hypothetical situation. We calculated the sample sizes required to detect an effect of a given magnitude with sufficient power and under different experimental setups. We demonstrated that the inclusion of both sexes in experimental setups, without testing for sex effects, requires no or few additional animals in our scenarios. These experimental designs still allow for the exploration of sex effects at low cost. In a confirmatory instead of an exploratory design, we observed an increase in total sample sizes by 33%, at most. Since the complexities associated with this mathematical model require statistical expertise, we generated and provide a sample size calculator for planning factorial design experiments. For the inclusion of sex, a factorial design is advisable, and a sex-specific analysis can be performed without excessive additional effort. Our easy-to-use calculation tool provides help in designing studies with both sexes and addresses the current sex bias in preclinical studies.
- Top Cited Papers
- 1 March 2019
- Published by Elsevier in Cell Host & Microbe
- Vol. 25 (3) , 389-403.e6
The Skin Commensal Yeast Malassezia Triggers a Type 17 Response that Coordinates Anti-fungal Immunity and Exacerbates Skin Inflammation
- 1 March 2019
- Published by Elsevier in Cell Host & Microbe
- Vol. 25 (3) , 389-403.e6
Top Cited PapersThe Skin Commensal Yeast Malassezia Triggers a Type 17 Response that Coordinates Anti-fungal Immunity and Exacerbates Skin Inflammation
- Open Access
- 3 November 2017
- Published by Springer Nature in Scientific Reports
- Vol. 7 (1) , 1-14
A high-throughput model for investigating neuronal function and synaptic transmission in cultured neuronal networks
Loss of synapses or alteration of synaptic activity is associated with cognitive impairment observed in a number of psychiatric and neurological disorders, such as schizophrenia and Alzheimer’s disease. Therefore successful development ofin vitromethods that can investigate synaptic function in a high-throughput format could be highly impactful for neuroscience drug discovery. We present here the development, characterisation and validation of a novel high-throughputin vitromodel for assessing neuronal function and synaptic transmission in primary rodent neurons. The novelty of our approach resides in the combination of the electrical field stimulation (EFS) with data acquisition in spatially separated areas of an interconnected neuronal network. We integrated our methodology with state of the art drug discovery instrumentation (FLIPR Tetra) and used selective tool compounds to perform a systematic pharmacological validation of the model. We investigated pharmacological modulators targeting pre- and post-synaptic receptors (AMPA, NMDA, GABA-A, mGluR2/3 receptors and Nav, Cav voltage-gated ion channels) and demonstrated the ability of our model to discriminate and measure synaptic transmission in cultured neuronal networks. Application of the model described here as an unbiased phenotypic screening approach will help with our long term goals of discovering novel therapeutic strategies for treating neurological disorders.
- 3 November 2017
- Published by Springer Nature in Scientific Reports
- Vol. 7 (1) , 1-14
Open AccessA high-throughput model for investigating neuronal function and synaptic transmission in cultured neuronal networks
Loss of synapses or alteration of synaptic activity is associated with cognitive impairment observed in a number of psychiatric and neurological disorders, such as schizophrenia and Alzheimer’s disease. Therefore successful development ofin vitromethods that can investigate synaptic function in a high-throughput format could be highly impactful for neuroscience drug discovery. We present here the development, characterisation and validation of a novel high-throughputin vitromodel for assessing neuronal function and synaptic transmission in primary rodent neurons. The novelty of our approach resides in the combination of the electrical field stimulation (EFS) with data acquisition in spatially separated areas of an interconnected neuronal network. We integrated our methodology with state of the art drug discovery instrumentation (FLIPR Tetra) and used selective tool compounds to perform a systematic pharmacological validation of the model. We investigated pharmacological modulators targeting pre- and post-synaptic receptors (AMPA, NMDA, GABA-A, mGluR2/3 receptors and Nav, Cav voltage-gated ion channels) and demonstrated the ability of our model to discriminate and measure synaptic transmission in cultured neuronal networks. Application of the model described here as an unbiased phenotypic screening approach will help with our long term goals of discovering novel therapeutic strategies for treating neurological disorders.
- 23 March 2017
- Published by Springer Nature in Psychopharmacology
- Vol. 234 (12) , 1803-1813
Phosphodiesterase-1b (Pde1b) knockout mice are resistant to forced swim and tail suspension induced immobility and show upregulation of Pde10a
Rationale Major depressive disorder is a leading cause of suicide and disability. Despite this, current antidepressants provide insufficient efficacy in more than 60% of patients. Most current antidepressants are presynaptic reuptake inhibitors; postsynaptic signal regulation has not received as much attention as potential treatment targets. Objectives We examined the effects of disruption of the postsynaptic cyclic nucleotide hydrolyzing enzyme, phosphodiesterase (PDE) 1b, on depressive-like behavior and the effects on PDE1B protein in wild-type (WT) mice following stress. Methods Littermate knockout (KO) and WT mice were tested in locomotor activity, tail suspension (TST), and forced swim tests (FST). FST was also used to compare the effects of two antidepressants, fluoxetine and bupropion, in KO versus WT mice. Messenger RNA (mRNA) expression changes were also determined. WT mice underwent acute or chronic stress and markers of stress and PDE1B expression were examined. Results Pde1b KO mice exhibited decreased TST and FST immobility. When treated with antidepressants, both WT and KO mice showed decreased FST immobility and the effect was additive in KO mice. Mice lacking Pde1b had increased striatal Pde10a mRNA expression. In WT mice, acute and chronic stress upregulated PDE1B expression while PDE10A expression was downregulated after chronic but not acute stress. Conclusions PDE1B is a potential therapeutic target for depression treatment because of the antidepressant-like phenotype seen in Pde1b KO mice.
- 23 March 2017
- Published by Springer Nature in Psychopharmacology
- Vol. 234 (12) , 1803-1813
Phosphodiesterase-1b (Pde1b) knockout mice are resistant to forced swim and tail suspension induced immobility and show upregulation of Pde10a
Rationale Major depressive disorder is a leading cause of suicide and disability. Despite this, current antidepressants provide insufficient efficacy in more than 60% of patients. Most current antidepressants are presynaptic reuptake inhibitors; postsynaptic signal regulation has not received as much attention as potential treatment targets. Objectives We examined the effects of disruption of the postsynaptic cyclic nucleotide hydrolyzing enzyme, phosphodiesterase (PDE) 1b, on depressive-like behavior and the effects on PDE1B protein in wild-type (WT) mice following stress. Methods Littermate knockout (KO) and WT mice were tested in locomotor activity, tail suspension (TST), and forced swim tests (FST). FST was also used to compare the effects of two antidepressants, fluoxetine and bupropion, in KO versus WT mice. Messenger RNA (mRNA) expression changes were also determined. WT mice underwent acute or chronic stress and markers of stress and PDE1B expression were examined. Results Pde1b KO mice exhibited decreased TST and FST immobility. When treated with antidepressants, both WT and KO mice showed decreased FST immobility and the effect was additive in KO mice. Mice lacking Pde1b had increased striatal Pde10a mRNA expression. In WT mice, acute and chronic stress upregulated PDE1B expression while PDE10A expression was downregulated after chronic but not acute stress. Conclusions PDE1B is a potential therapeutic target for depression treatment because of the antidepressant-like phenotype seen in Pde1b KO mice.
- 1 December 2016
- Published by SAGE Publications in Laboratory Animals
- Vol. 50 (6) , 427-432
The more the merrier? Scoring, statistics and animal welfare in experimental autoimmune encephalomyelitis
Experimental autoimmune encephalomyelitis (EAE) is a frequently used animal model for the investigation of autoimmune processes in the central nervous system. As such, EAE is useful for modelling certain aspects of multiple sclerosis, a human autoimmune disease that leads to demyelination and axonal destruction. It is an important tool for investigating pathobiology, identifying drug targets and testing drug candidates. Even though EAE is routinely used in many laboratories and is often part of the routine assessment of knockouts and transgenes, scoring of the disease course has not become standardized in the community, with at least 83 published scoring variants. Varying scales with differing parameters are used and thus limit comparability of experiments. Incorrect use of statistical analysis tools to assess EAE data is commonplace. In experimental practice the clinical score is used not only as an experimental readout, but also as a parameter to determine animal welfare actions. Often overlooked factors such as the animal’s ability to sense its compromised motoric abilities, drastic though transient weight loss, and also the possibility of neuropathic pain, make the assessment of severity a difficult task and pose a problem for experimental refinement.
- 1 December 2016
- Published by SAGE Publications in Laboratory Animals
- Vol. 50 (6) , 427-432
The more the merrier? Scoring, statistics and animal welfare in experimental autoimmune encephalomyelitis
Experimental autoimmune encephalomyelitis (EAE) is a frequently used animal model for the investigation of autoimmune processes in the central nervous system. As such, EAE is useful for modelling certain aspects of multiple sclerosis, a human autoimmune disease that leads to demyelination and axonal destruction. It is an important tool for investigating pathobiology, identifying drug targets and testing drug candidates. Even though EAE is routinely used in many laboratories and is often part of the routine assessment of knockouts and transgenes, scoring of the disease course has not become standardized in the community, with at least 83 published scoring variants. Varying scales with differing parameters are used and thus limit comparability of experiments. Incorrect use of statistical analysis tools to assess EAE data is commonplace. In experimental practice the clinical score is used not only as an experimental readout, but also as a parameter to determine animal welfare actions. Often overlooked factors such as the animal’s ability to sense its compromised motoric abilities, drastic though transient weight loss, and also the possibility of neuropathic pain, make the assessment of severity a difficult task and pose a problem for experimental refinement.
- Open Access
- 5 January 2016
- Published by Springer Nature in Translational Psychiatry
- Vol. 6 (1) , e707
Absence of IFNγ promotes hippocampal plasticity and enhances cognitive performance
Cognitive functioning can be differentially modulated by components of the immune system. Interferon-γ (IFNγ) is a pro-inflammatory cytokine whose production is altered in many conditions displaying some degree of cognitive deficits, although its role in cognitive functioning is still unclear. Here we show that the absence of IFNγ selectively enhances cognitive behaviours in tasks in which the hippocampus is implicated. Moreover, the absence of IFNγ leads to volumetric and cell density changes that are restricted to the dorsal part of the hippocampus. In the dorsal hippocampus, the absence of this pro-inflammatory cytokine leads to an increase in the numbers of newly born neurons in the subgranular zone of the dentate gyrus (DG), an adult neurogenic niche known to support learning and memory, and to an enlargement of the dendritic arborization of DG granule and cornu ammonis (CA)1 pyramidal neurons. Moreover, it also modestly impacts synaptic plasticity, by decreasing the paired-pulse facilitation in the Schaffer collateral to CA1 pyramidal cell synapses. Taken together, our results provide evidence that IFNγ is a negative regulator of hippocampal functioning, as its absence positively impacts on dorsal hippocampus structure, cell density, neuronal morphology and synaptic plasticity. Importantly, these neuroplastic changes are associated with improved performance in learning and memory tasks. Therefore, blockage of the IFNγ signalling may present as promising therapeutic targets for the treatment of inflammation-associated cognitive dysfunction.
- 5 January 2016
- Published by Springer Nature in Translational Psychiatry
- Vol. 6 (1) , e707
Open AccessAbsence of IFNγ promotes hippocampal plasticity and enhances cognitive performance
Cognitive functioning can be differentially modulated by components of the immune system. Interferon-γ (IFNγ) is a pro-inflammatory cytokine whose production is altered in many conditions displaying some degree of cognitive deficits, although its role in cognitive functioning is still unclear. Here we show that the absence of IFNγ selectively enhances cognitive behaviours in tasks in which the hippocampus is implicated. Moreover, the absence of IFNγ leads to volumetric and cell density changes that are restricted to the dorsal part of the hippocampus. In the dorsal hippocampus, the absence of this pro-inflammatory cytokine leads to an increase in the numbers of newly born neurons in the subgranular zone of the dentate gyrus (DG), an adult neurogenic niche known to support learning and memory, and to an enlargement of the dendritic arborization of DG granule and cornu ammonis (CA)1 pyramidal neurons. Moreover, it also modestly impacts synaptic plasticity, by decreasing the paired-pulse facilitation in the Schaffer collateral to CA1 pyramidal cell synapses. Taken together, our results provide evidence that IFNγ is a negative regulator of hippocampal functioning, as its absence positively impacts on dorsal hippocampus structure, cell density, neuronal morphology and synaptic plasticity. Importantly, these neuroplastic changes are associated with improved performance in learning and memory tasks. Therefore, blockage of the IFNγ signalling may present as promising therapeutic targets for the treatment of inflammation-associated cognitive dysfunction.